A $4.8 Billion Reason to Buy BioMarin Stock Today

BioMarin (BMRN) shares closed roughly 20% higher on Dec. 19 after announcing a $4.8 billion acquisition of Philadelphia-headquartered Amicus Therapeutics (FOLD). The all-cash transaction values each FOLD share at $14.50, a 33% premium over their previous close, indicating BioMarin’s commitment to expanding its footprint in the rare disease market. More News from Barchart Despite the recent rally, BioMarin stock is down some 18% versus its year-to-date high set in late March. www.barchart.com Signific ...